Theriva Biologics Faces Financial and Clinical Crossroads Theriva Biologics has completed enrollment for its VIRAGE Phase 2b trial targeting metastatic pancreatic cancer, with results expected in Q2 2025. Despite regulatory progress, including FDA Fast Track designation, its limited cash reserves, projected to last only until Q3 2025, raise concerns about the company’s financial stability.2